The purpose of this study is to determine whether a commonly used cholesterol-lowering therapies can help recruit antitumor immune cells into a prostate tumor. The study focuses on people with prostate cancer who have elected to monitor their cancer under active surveillance and who will have a standard-of-care biopsy in 3-6 months. Study procedures include receiving medication (usually Vytorin but can differ depending on cholesterol level and any current anti-cholesterol therapy), undergoing blood tests, and completing questionnaires. All study medications are approved by the U.S. Food and Drug Administration (FDA) for cholesterol-lowering, but their use in this study is considered experimental because it has not been approved to stop the growth of prostate cells in individuals with prostate cancer.
Not Available
What is the full name of this clinical trial?
Intensive Cholesterol-Lowering and CD8+ T Cells in Prostate Cancer